JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Suletud

12.08 -0.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.92

Max

12.13

Põhinäitajad
By Trading Economics
Sissetulek	-4.1M -72M
Töötajad	205
EBITDA	-1.2M -74M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+62.72% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2025

Turustatistika
By TradingEconomics
Turukapital	1.1B 1.7B
Eelmine avamishind	12.41
Eelmine sulgemishind	12.08

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. juuli 2025, 17:53 UTC

Suurimad hinnamuutused turgudel

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. juuli 2025, 15:58 UTC

Tulu

Suurimad hinnamuutused turgudel

Aon Shares Rise After 2Q Earnings Beat

25. juuli 2025, 15:08 UTC

Suurimad hinnamuutused turgudel

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. juuli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. juuli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. juuli 2025, 20:40 UTC

Tulu

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. juuli 2025, 20:10 UTC

Tulu

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 19:56 UTC

Tulu

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. juuli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. juuli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. juuli 2025, 19:01 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. juuli 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. juuli 2025, 17:38 UTC

Suurimad hinnamuutused turgudel

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. juuli 2025, 17:13 UTC

Tulu

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. juuli 2025, 16:46 UTC

Tulu

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. juuli 2025, 16:45 UTC

Tulu

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. juuli 2025, 16:27 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. juuli 2025, 16:02 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. juuli 2025, 15:34 UTC

Tulu

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. juuli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. juuli 2025, 15:05 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. juuli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. juuli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. juuli 2025, 14:36 UTC

Market Talk

Tulu

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

62.72% tõus

12 kuu keskmine prognoos

Keskmine 19.64 USD 62.72%

Kõrge 29 USD

Madal 9 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.